(Q52600412)

English

Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.

scientific article published on 7 April 2018

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5958153

Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials. (English)

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5958153

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

6

object named as

G Kees Hovingh

0 references

author name string

Harold E Bays

1

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5958153

Robert S Rosenson

2

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5958153

Marie T Baccara-Dinet

3

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5958153

Michael J Louie

4

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5958153

Desmond Thompson

5

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5958153

G Kees Hovingh

6

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5958153

publication date

1 April 2018

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5958153

Cardiovascular Drugs and Therapy

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5958153

32

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5958153

175-180

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5958153

2

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5958153

copyright license

Creative Commons Attribution 4.0 International

1 April 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5958153

16 June 2018

Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5958153

16 June 2018

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5958153

16 June 2018

Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5958153

16 June 2018

Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5958153

16 June 2018

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5958153

16 June 2018

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5958153

16 June 2018

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5958153

16 June 2018

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5958153

16 June 2018

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5958153

16 June 2018

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5958153

16 June 2018

Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5958153

13 August 2018

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5958153

13 August 2018

Antidrug Antibodies in Patients Treated with Alirocumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5958153

13 August 2018

Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5958153

13 August 2018

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5958153

30 November 2018

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5958153

30 November 2018

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627892

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10557-018-6784-Z

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5958153

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5958153

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5958153

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52600412&oldid=1895485454"